2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | LANCET LANCET （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.7
61人评分
我要评分
声誉 9.8 影响力 9.8 速度 9.2 | |||||||||||||||||
| 期刊ISSN | 0140-6736 | 微信扫码收藏此期刊 | ||||||||||||||||
| E-ISSN | 1474-547X | |||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 168.9 点击查看影响因子趋势图 | |||||||||||||||||
| 实时影响因子 | 截止2023年6月16日：115.677 | |||||||||||||||||
| 2022-2023自引率 | 0.70%点击查看自引率趋势图 | |||||||||||||||||
| 五年影响因子 | 118.1 | |||||||||||||||||
| h-index | 700 | |||||||||||||||||
| CiteScore |
| |||||||||||||||||
| 期刊简介 | The Lancet is an international general medical journal that will consider any original contribution that advances or illuminates medical science or practice, or that educates or entertains the journal's readers. Whatever you have written, remember that it is the general reader whom you are trying to reach. One way to find out if you have succeeded is to show your draft to colleagues in other specialties. If they do not understand, neither, very probably, will The Lancet's staff or readers. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. | |||||||||||||||||
| 期刊官方网站 | http://www.thelancet.com/ | |||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/THELANCET | |||||||||||||||||
| 期刊语言要求 | Language Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足LANCET的语言要求，还能让LANCET编辑和审稿人得到更好的审稿体验，让稿件最大限度地被LANCET编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||
| 出版商 | Elsevier Ltd | |||||||||||||||||
| 涉及的研究方向 | 医学-医学：内科 | |||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||
| 出版语言 | English | |||||||||||||||||
| 出版周期 | Weekly | |||||||||||||||||
| 出版年份 | 1823 | |||||||||||||||||
| 年文章数 | 223点击查看年文章数趋势图 | |||||||||||||||||
| Gold OA文章占比 | 21.18% | |||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 72.20% | |||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） | （没有被2021年的JCR升级版收录，仅供参考） | |||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0140-6736%5BISSN%5D | |||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均3月 | |||||||||||||||||
| 平均录用比例 | 网友分享经验： 约50% | |||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在LANCET顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Author: Hurvitz, Sara A.; Hegg, Roberto; Chung, Wei-Pang; Im, Seock-Ah; Jacot, William; Ganju, Vinod; Chiu, Joanne Wing Yan; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altintas, Sevilay; Henning, Jan-Willem; Curigliano, Giuseppe; Perez-Garcia, Jose Manuel; Kim, Sung-Bae; Petry, Vanessa; Huang, Chiun-Sheng; Li, Wei; Frenel, Jean-Sebastien; Antolin, Silvia; Yeo, Winnie; Bianchini, Giampaolo; Loi, Sherene; Tsurutani, Junji; Egorov, Anton; Liu, Yali; Cathcart, Jillian; Ashfaque, Shahid; Cortes, Javier Journal: LANCET. 2023; Vol. 401, Issue 10371, pp. 105-117. DOI: 10.1016/S0140-6736(22)02420-5 PubMed DOI |
| 2. | Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferioritytrial Author: Wang, Yongjun; Li, Shuya; Pan, Yuesong; Li, Hao; Parsons, Mark W.; Campbell, Bruce C., V; Schwamm, Lee H.; Fisher, Marc; Che, Fengyuan; Dai, Hongguo; Li, Deyang; Li, Runhui; Wang, Junhai; Wang, Yilong; Zhao, Xingquan; Li, Zixiao; Zheng, Huaguang; Xiong, Yunyun; Meng, Xia Journal: LANCET. 2023; Vol. 401, Issue 10377, pp. 645-654. DOI: 10.1016/S0140-6736(22)02600-9 PubMed DOI |
| 3. | Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis Author: Pan, Yang; Wang, Liang; Feng, Zhaomin; Xu, Hui; Li, Fu; Shen, Ying; Zhang, Daitao; Liu, William J.; Gao, George F.; Wang, Quanyi Journal: LANCET. 2023; Vol. 401, Issue 10377, pp. 664-672. DOI: 10.1016/S0140-6736(23)00129-0 PubMed DOI |
| 4. | Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials Author: Kimball, Alexa B.; Jemec, Gregor B. E.; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B.; Bechara, Falk G.; Paul, Carle; Bourboulis, Evangelos J. Giamarellos; Villani, Axel P.; Schwinn, Andreas; Rueff, Franziska; Ramaya, Larisha Pillay; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Martorell, Antonio; Mendes-Bastos, Pedro; Kokolakis, Georgios; Becherel, Pierre-Andre; Wozniak, Magdalena B.; Martinez, Angela Llobet; Wei, Xiaoling; Uhlmann, Lorenz; Passera, Anna; Keefe, Deborah; Martin, Ruvie; Field, Clarice; Chen, Li; Vandemeulebroecke, Marc; Ravichandran, Shoba; Muscianisi, Elisa Journal: LANCET. 2023; Vol. 401, Issue 10378, pp. 747-761. DOI: 10.1016/S0140-6736(23)00022-3 PubMed DOI |
| 5. | Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial Author: You, Rui; Liu, You -Ping; Xie, Yu -Long; Lin, Chao; Duan, Chong -Yang; Chen, Dong-Ping; Pan, Yi; Qi, Bin; Zou, Xiong; Guo, Ling; Cao, Jing-Yu; Zhang, Yi-Nuan; Wang, Zhi-Qiang; Liu, Yong -Long; Ouyang, Yan-Feng; Wen, Kai; Yang, Qi; Xie, Ruo-Qi; Li, Hui-Feng; Duan, Xiao-Tong; Ding, Xi; Peng, Lan; Chen, Si -Yuan; Liang, Jiong-Lin; Feng, Zheng-Kai; Xia, Tian-Liang; Xie, Rui-Ling; Jiang, Rou; Gu, Chen-Mei; Liu, Rong-Zeng; Sun, Rui; Yang, Xin; Liu, Li-Zhi; Ling, Li; Liu, Qing; Ng, Wai Tong; Hua, Yi-Jun; Huang, Pei-Yu; Chen, Ming-Yuan Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 917-927. DOI: 10.1016/S0140-6736(23)00269-6 PubMed DOI |
| 6. | Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomisedtrial Author: He, Jiang; Ouyang, Nanxiang; Guo, Xiaofan; Sun, Guozhe; Li, Zhao; Mu, Jianjun; Wang, Dao Wen; Qiao, Lixia; Xing, Liying; Ren, Guocheng; Zhao, Chunxia; Yang, Ruihai; Yuan, Zuyi; Wang, Chang; Shi, Chuning; Liu, Songyue; Miao, Wei; Li, Guangxiao; Chen, Chung-Shiuan; Sun, Yingxian; CRHCP Study Grp Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 928-938. DOI: 10.1016/S0140-6736(22)02603-4 PubMed DOI |
| 7. | Malnutrition in older adults Author: Dent, Elsa; Wright, Olivia R. L.; Woo, Jean; Hoogendijk, Emiel O. Journal: LANCET. 2023; Vol. 401, Issue 10380, pp. 951-966. DOI: 10.1016/S0140-6736(22)02612-5 PubMed DOI |
| 8. | Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial Author: Mingguang He, Yuzhen Jiang, Shengsong Huang, Dolly S Chang, Beatriz Munoz, Tin Aung, Paul J Foster, David S Friedman Journal: LANCET, 2019, Vol., , DOI:10.1016/s0140-6736(18)32607-2 DOI |
| 9. | The KEYNOTE-061 trial Author: Fei Liang Journal: LANCET, 2019, Vol.393, 1098, DOI:10.1016/s0140-6736(18)33073-3 DOI |
| 10. | Strengthening the legal framework to regulate human genetic engineering in China Author: Cao Yanlin, Zheng Xueqian, Jia Fei Journal: LANCET, 2019, Vol.393, 1097, DOI:10.1016/s0140-6736(19)30294-6 DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共16条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
